Tumor Treating Fields (TTF) Electrical Cancer Therapy

Therapy | Treatment

Tumor Treating Fields (TTF)
Electrical Cancer Therapy

Treating cancer with low-intensity electrical fields to suppress cancer cell proliferation.

What is TTF?MechanismsAdaptationTreatment methodsSafetyCost |

What is Tumor Treating Fields (TTF) therapy?

Tumor Treating Fields (TTF) therapy is a type of electromagnetic field therapy using low-intensity electrical fields to suppress cancer cell proliferation in the body.

This treatment dates back a long time. TTF is a treatment to generate electrical fields in the human body, leading to the suppression of local cancer cell proliferation. With this treatment, cancer cells can be destroyed, triggering apoptosis. This is the basic concept of TTF. Normal cells on intestinal mucosa can proliferate, but since cancer cells are smaller than normal cells, cancer cells don't destroy normal cells.

Effectiveness of the treatment

The effectiveness of TTF is considered to be similar to that of chemotherapy. However, chemotherapy has side effects which destroy normal cells as well. It is not recommended to be used for long term treatment because of drug resistance and accumulation of toxicity. TTF on the other hand is considered a safe treatment which doesn’t have any problems in terms of drug resistance and accumulation of toxicity . Also, it is possible to use TTF with other conventional treatments such as chemotherapy. We believe that there are synergistic effects using TTF with immunotherapy, especially GcMAF macrophage activating factor. We recommend GcMAF be used in combination with TTF for best results and to achieve complete systemic treatment.

Treatment example of brain tumors and breast cancer



We have published a number of examples that were treated with brain tumors and breast cancer by an electric field therapy with photos.

→ Download PDF

Mechanisms of TTF

In general

  • It generates low-intensity electrical fields to consistently destroy cancer cells.
  • Electrical fields do exist around the place where electric current flows.
  • Electrical fields attract the substances that have electrical charge.
  • It behaves in a similar way to gravity.
  • It suppresses cancer cell proliferation.

At the cellular level 1

  • The electrical fields are even in the undivided cells.
  • Cell division is categorized into mitosis which is the nucleus division through the fast and highly complex process and cytokinesis which is the cytoplasm division into two.
  • As the early stage in mitosis, the spindle starts to be formed by the polymerization of the microtubule.
  • Under the existence of the electrical fields, the polymerization is impeded and that leads to the mitotic arrest because each microtubule is arranged along the electrical fields.

At the cellular level 2

  • In the cells where the spindle formation has completed, the cell starts to divide into two.
  • While the division is occurring, because the form of the cell becomes a sandglass-type, the electric field distribution becomes uneven.
  • As a result, cell components get pushed into the constricted part, and the cell gets destroyed.

Treatment applications of TTF

Although this treatment is mainly used for the patients with malignant glioblastoma, lung cancer and breast cancer, it is also considered to treat almost all of the solid cancers such as brain tumors, metastatic lung cancer, esophageal cancer, throat cancer, laryngeal cancer, stomach cancer, liver cancer, metastatic liver cancer, pancreatic cancer, colon cancer, ovarian cancer, uterine cancer, kidney cancer, prostate cancer, bladder cancer and sarcoma.

Treatment method

Common configuration patients wear a helmet mask and a vest or short pants. Configuration may vary depending on the type of cancer.

The vest and helmet worn for treatment is sized to fit each patient and sometimes made to order depending on the type of cancer and location. The electric fields treatment is prepared for each patient after accessing disease information and scans. This treatment is used daily in your home.

Blanket (sleeping bag) type TTF device for use in combination with jacket and helmet devices.

Tumor Treating Fields (TTF) jacket

TTF helmet

TTF long coat for extra coverage treatment

TTF sleeping bag blanket



Devices are powered by 2 AA size batteries (not included). We recommend rechargeable AA size batteries (approx. 2000 mAh) such as Panasonic/Sanyo Eneloop AA size rechargeable batteries or equivalent product.

For operation: 2 AA size batteries for Power Supply, 2 AA size batteries for Detector, and 2 or more spare AA size batteries for uninterrupted operation.

Safety and side effects of TTF

This treatment does not affect normal cells so there are much less side effects reported compared to chemotherapy. No serious side effects have been reported.

Information required for TTF

  • Name of Disease:
  • Metastasis (location of tumors):

  • Head circumference (cm):
  • Upper chest circumference (cm):
  • Waist circumference (cm):
  • Hip circumference (cm):
  • Height (cm):
  • Weight (kg):
  • Age of patient:

If you have a recent MRI, CT or PET scan, please save image files (such as .jpg format) of sections showing the tumor areas and email them to us.

Cost

  • TTF treatment set - 864,000 yen *

  • TTF treatment set including sleeping bag blanket - 1,080,000 yen *

  • Please add 15,000 yen for worldwide shipping and handling.
  • Payment is by wire transfer.
  • Exact configuration of treatment set will vary slightly depending on the type of cancer and location of tumors and risk of metastasis.
  • Devices are powered by 2 AA size batteries (not included). We recommend rechargeable AA size batteries (approx. 2000 mAh).
Contact us to place your order.

News

Heart Pharmacy website gcmaf.co.jp is now open

Purchase your Colostrum MAF here using PayPal or credit card.

Heart Pharmacy website


2016 Integrative Medical Therapies Conference - Osaka, Japan

Thank you very much for your participation at the Saisei Mirai 2016 Integrative Medical Therapies conference in Osaka, held on Sunday 13th November 2016.

2016 Integrative Medical Therapies conference - Osaka, Japan


Genostics Conference - Sydney, Australia

24-SEP-2016
Dr Toshio Inui

Genostics official website


Symposium on Integrated Medicine: Electric Fields Therapy & Immunotherapy - Jakarta, Indonesia


22-JUL-2016
Dr. Toshio Inui gave a presentation of the electric field therapy and second-generation GcMAF and colostrum MAF at a conference which was held in Jakarta, Indonesia on July 22, 2016.



International Pharmacy Conference

14 to 15-JUL-2016
Dr. Shinichiro Akiyama at International Pharmacy Conference, which was held in the United States Philadelphia, Pennsylvania on July 14 to 15, 2016, the Clinical experience of colostrum derived protein against solid cancer has been announced as the Keynote Speaker.



New New research papers published by Saisei Mirai in Anticancer Research available online.

Research paper
2016 Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis (PDF)
ANTICANCER RESEARCH 36: 3771-3774 (2016)

Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis

Research paper
2016 Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields (PDF)
ANTICANCER RESEARCH 36: 3767-3770 (2016)

Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields

Research paper
2016 Macrophages Exhibit a Large Repertoire of Activation States via Multiple Mechanisms of Macrophage-activating Factors (PDF)
ANTICANCER RESEARCH 36: 3619-3624 (2016)

Macrophages Exhibit a Large Repertoire of Activation States via Multiple Mechanisms of Macrophage-activating Factors Macrophages Exhibit a Large Repertoire of Activation States via Multiple Mechanisms of Macrophage-activating Factors Macrophages Exhibit a Large Repertoire of Activation States via Multiple Mechanisms of Macrophage-activating Factors

New research papers published by Saisei Mirai in Anticancer Research available online.

New research papers on Oral Colostrum GcMAF for Chronic Fatigue Syndrome (CFS) and serious infection published in Anticancer Research journal.

Research paper
2015 Oral Colostrum Macrophage-activating Factor for Serious Infection and Chronic Fatigue Syndrome: Three Case Reports (PDF)
Anticancer Res August 2015 35 (8) 4545-4549

Conference presentation - 10th International Congress for Medical Laser Applications, Germany

13-JUN-2015
Clinical application of Second Generation GcMAF and oral GcMAF
Dr Toshio Inui

Clinical application of Second Generation GcMAF and oral GcMAF
ISLA website

Conference presentation - 9th International Congress for Medical Laser Applications, Germany

29-JUN-2014
Indications for GcMAF for immunotherapy of cancers and chronic viral and bacterial infections (PDF)

Dr Toshio Inui

Dr Toshio Inui Indications for GcMAF for immunotherapy of cancers and chronic viral and bacterial infections

Conference presentation - The 17th Annual Meeting of The Society of Biotherapeutic Approaches, Fukuoka University

7-DEC-2013
Case Report: A Breast Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Hormone Therapy (PDF), PPT

Dr Toshio Inui

Dr Toshio Inui Case Report - A Breast Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Hormone Therapy

New research papers published by Saisei Mirai in Anticancer Research available online.

New research papers on GcMAF and integrative cancer immunotherapy treatment written in collaboration with the University of Tokushima, Kanazawa University and Kobe University Graduate School of Medicine researchers and Saisei Mirai published in Anticancer Research journal.

Research paper
2013 Degalactosylated/Desialylated Human Serum Containing GcMAF Induces Macrophage Phagocytic Activity and In Vivo Antitumor Activity (PDF)
Anticancer Res July 2013 33 (7) 2881-2885

Cancer vaccine therapy - autologous tissue derived tumor vaccine Cancer vaccine therapy - autologous tissue derived tumor vaccine Cancer vaccine therapy - autologous tissue derived tumor vaccine

Research paper
2013 Clinical Experience of Integrative Cancer Immunotherapy with GcMAF (PDF)
Anticancer Res July 2013 33 (7) 2917-2919

Cancer vaccine therapy - autologous tissue derived tumor vaccine Cancer vaccine therapy - autologous tissue derived tumor vaccine Cancer vaccine therapy - autologous tissue derived tumor vaccine

Nature Outlook sponsored article

For more details on GcMAF see our GcMAF page.



Experiment report of Gc MAF stability assay
14-JUN-2012 Stability of GcMAF in Serum (PDF)
H Mukai, Y Uto. Department of Biological Science and Technology, The University of Tokushima.

Stability of GcMAF in Serum report Stability of GcMAF in Serum report

The results show that 2nd Generation GcMAF is stable for 1 year at 4 °C, for 14 days at room temperature (around 20 °C), and for 7 days at 40 °C.

See Research and references for more details on experiments on macrophage phagocytic activity and stability of our GcMAF.


Collaborations with the University of Tokushima
We collaborate with GcMAF researchers at the University of Tokushima, Japan in the development of second generation GcMAF. See Research and references for published research papers on Gc-MAF in peer-reviewed scientific journals authored by the University of Tokushima researchers over the last decade. Our research on GcMAF is ongoing and papers are being prepared for publication in collaboration between the University of Tokushima and Saisei Mirai in the next few months.


University of Tokushima, Institute of Technology and Science, Laboratory Research

Our research group:
Imagin-K
Contact us
Treatments and therapies
Contact us

Saisei Mirai Clinics
Kobe Saisei Mirai Clinic
  • Cancer
  • Skin regeneration
  • Skin rejuvenation
  • Anti-aging
Kobe Saisei Mirai Clinic

Boeki Center Building
23rd Floor
5-1-14 Hamabetori Chuo-ku
Kobe-shi
Hyogo-ken 651-0083
Japan


Inui Cancer
Immunotherapy Clinic
  • Cancer
  • Hepatitis
  • Chronic diseases
Inui Cancer Immunotherapy Clinic

6-14-17 Kindachou
Moriguchi-shi
Osaka 570-0011
Japan
TEL: +81 (0)6-6902-5251
FAX: +81 (0)6-6902-7133

Inui Cancer Immunotherapy Clinic

Keihan Clinic
  • Cancer
  • Hepatitis
  • Chronic diseases
  • Anti-aging
Saisei Mirai Keihan Clinic

Nature 21 Building
2nd Floor
3-34-8 Okubo-cho
Moriguchi-shi
Osaka 570-0012
Japan
TEL: +81 (0)6-6902-1001


R Future Cancer Int'l Clinic
  • Cancer
R Future Cancer Int'l Clinic

ORE Hiroo Building
7th Floor
5-10-26 Minamiazabu
Minato-ku
Tokyo-to 106-0047
Japan


R Science Clinic
  • Skin regeneration
  • Skin rejuvenation
  • Anti-aging
R Mirai Clinic

ORE Hiroo Building
6th Floor
5-10-26 Minamiazabu
Minato-ku
Tokyo-to 106-0047
Japan


Immunotherapy Lab
  • Cell Processing Center
Immunotherapy Lab

Nature 21 Building
3rd Floor
3-34-8 Okubo-cho
Moriguchi-shi
Osaka 570-0012
Japan